Resveratrol and Blood Pressure: Heart Health, Endothelial Function & Evidence

Resveratrol may modestly improve some cardiovascular risk markers, but it is not a proven cardiovascular therapy. The strongest 2026 umbrella evidence supports blood-pressure effects in selected populations—especially people with type 2 diabetes—while small randomized trials also show improvements in endothelial function.

The important distinction is that better endothelial function is not the same as lower blood pressure, and neither is the same as fewer heart attacks or strokes.

Resveratrol and heart health at a glance

Outcome	Evidence position	Interpretation
Systolic blood pressure	Possible modest reduction	Supported in some pooled analyses and high-certainty subgroup evidence in T2D.
Diastolic blood pressure	Possible modest reduction	Similar pattern; not consistent in every individual trial.
Flow-mediated dilation (FMD)	Promising	Several small trials report improved endothelial responsiveness.
LDL / triglycerides	Mixed to modest	Recent pooled evidence reports favorable changes in selected populations.
Heart failure function	Exploratory positive signal	One small trial reported functional and inflammatory improvements.
Peripheral artery disease walking	Null/inconclusive	RESTORE did not show convincing clinically meaningful improvement.
Heart attacks / strokes / mortality	Not established	No large outcome trial demonstrates cardiovascular-event prevention.

What does the 2026 high-level evidence show?

The 2026 umbrella review evaluated 45 systematic reviews and 129 associations across resveratrol outcomes. Among the relatively small group of high-certainty findings were reductions in systolic and diastolic blood pressure in people with type 2 diabetes.

A separate 2026 meta-analysis of 40 randomized trials and 2,551 participants also reported pooled reductions in systolic and diastolic blood pressure alongside improvements in selected lipids and inflammatory markers.

These are meaningful signals, but they remain risk-factor outcomes. Neither analysis demonstrates that resveratrol prevents cardiovascular events.

Endothelial function: one of resveratrol's strongest vascular signals

The endothelium is the inner lining of blood vessels and plays an important role in vascular tone and nitric-oxide signaling. Researchers often assess endothelial function using flow-mediated dilation (FMD) of the brachial artery.

Several controlled resveratrol studies have reported improved FMD.

Wong 2011: acute dose-response effect

In a double-blind randomized crossover trial of 19 adults with overweight or obesity and mildly elevated blood pressure, single resveratrol doses of 30, 90 and 270 mg produced a dose-related increase in FMD.

This provided a strong acute physiological signal—but it was still a small, single-dose study using a surrogate endpoint.

Wong 2013: chronic FMD improved, blood pressure did not

A later crossover trial in 28 otherwise healthy adults with obesity used 75 mg/day of trans-resveratrol for six weeks.

Brachial FMD improved versus placebo. Yet blood pressure and arterial compliance did not significantly change.

This is an important lesson: an endothelial-function benefit should not automatically be rewritten as a blood-pressure benefit.

Marques 2018: hypertensive adults

A randomized crossover trial in 24 treated hypertensive adults with endothelial dysfunction used a single 300 mg dose of trans-resveratrol.

FMD improved mainly in women and participants with higher LDL cholesterol, but brachial and aortic blood pressure did not significantly change.

Again, vascular responsiveness and measured blood pressure behaved differently.

What about people with coronary artery disease?

A small randomized trial in 40 people with stable post-infarction coronary artery disease used only 10 mg/day for three months.

The study reported improvements in diastolic function and FMD and a reduction in LDL cholesterol, while ejection fraction did not significantly improve.

This is promising but far from proof of cardioprotection in the sense consumers usually understand it. The trial did not test recurrent heart attacks, hospitalization or cardiovascular mortality.

Resveratrol and heart failure

A 2020 randomized placebo-controlled trial enrolled 60 people with NYHA class II–III systolic heart failure and used 100 mg/day for three months.

The resveratrol group showed improvements in several measures of cardiac function, six-minute walking performance, quality of life and inflammatory markers.

This deserves attention, but the trial was small, single-center, short and measured multiple endpoints. It should be viewed as a signal requiring larger replication, not as evidence that resveratrol treats heart failure.

Peripheral artery disease: a more sobering trial

The RESTORE randomized clinical trial studied 66 older adults with peripheral artery disease and compared 125 mg/day, 500 mg/day and placebo for six months.

It did not find convincing evidence that resveratrol improved walking performance. The 125 mg group showed a signal, but it did not reach a clinically meaningful difference; 500 mg showed no benefit.

This prevents a broad claim that resveratrol improves circulation enough to enhance function in established vascular disease.

Does resveratrol lower blood pressure?

Sometimes, modestly, in pooled analyses. The effect appears more consistent in selected higher-risk populations than in healthy people.

But individual trials demonstrate why expectations should remain conservative. Several FMD studies improved vascular responsiveness without significantly lowering blood pressure.

Blood pressure is influenced by baseline hypertension, medication use, dose, duration, body composition and metabolic status. A pooled mean effect cannot predict one person's response.

How much can blood pressure fall?

The exact pooled effect varies by meta-analysis and population. Rather than treating one summary number as universal, the better conclusion is that average reductions are generally modest and do not approach the evidence base of established antihypertensive medications.

People taking blood-pressure drugs should not reduce therapy because they add resveratrol.

Does resveratrol increase nitric oxide?

Nitric-oxide-related endothelial signaling is one plausible mechanism for the FMD findings. Experimental studies strongly support vascular signaling effects, but the clinical endpoint that matters is what happens in people.

Human FMD improvement is useful evidence of vascular responsiveness. It still does not prove long-term prevention of atherosclerosis or cardiovascular events.

Does resveratrol lower cholesterol?

Recent pooled evidence suggests reductions in total cholesterol, LDL cholesterol and triglycerides in some analyses. The effect is not universal and can differ by health condition.

For example, the six-month Bo diabetes trial found no broad metabolic benefit and even observed slight increases in total cholesterol and triglycerides in the 500 mg arm.

That is why one pooled lipid estimate should not be presented as a guaranteed individual response.

Does resveratrol prevent atherosclerosis?

No human clinical evidence demonstrates prevention or regression of atherosclerotic cardiovascular disease as a hard outcome. FMD, inflammatory markers and lipid changes are intermediate measures.

To establish prevention, we would need large long-term trials showing fewer cardiovascular events or validated imaging progression—not simply better biomarkers.

Can resveratrol prevent heart attacks or strokes?

Not proven. There are no large randomized cardiovascular-outcome trials demonstrating fewer myocardial infarctions, strokes or cardiovascular deaths with resveratrol.

This is one of the most important boundaries for supplement claims.

Can resveratrol replace blood-pressure medication?

No. The effect size and evidence quality are not comparable to validated antihypertensive therapy.

Stopping or reducing medication based on supplement use can expose a person to uncontrolled hypertension and cardiovascular risk.

Medication interactions matter in heart patients

People with cardiovascular disease often take statins, antiplatelet agents, anticoagulants, beta-blockers, ACE inhibitors, ARBs or other drugs. Resveratrol has direct human evidence of altering multiple CYP enzymes and has platelet-related biological activity.

See Resveratrol Drug Interactions.

What dose has been studied for cardiovascular outcomes?

Human vascular studies span a remarkably wide range:

• single 30–270 mg doses in acute FMD research
• 75 mg/day in chronic FMD work
• 10 mg/day in a small coronary-disease trial
• 100 mg/day in a heart-failure study
• 125 or 500 mg/day in the RESTORE PAD trial

There is no established “heart-health dose.”

Bottom line

Resveratrol's cardiovascular evidence is strongest for modest risk-factor and endothelial-function signals—not for cardiovascular-event prevention.

Small trials repeatedly show that FMD can improve, but blood pressure may remain unchanged in the same participants. Recent meta-analyses support modest blood-pressure effects in selected populations, while disease-specific trials range from promising heart-failure signals to a null peripheral-artery-disease trial.

For the broader evidence, see Resveratrol Benefits, Resveratrol and Diabetes and our Resveratrol Supplement guide. The full vascular trial library is in the Resveratrol Data Center.